Marta Lorenzo

Marta Lorenzo

Auto-generated profile, based on publicly available information

Marta Lorenzo

Department of Pathology, Hospital del Mar-Parc de Salut Mar-IMIM, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
SHSilvia Hernández-Llodrà
Silvia Hernández-Llodrà
NJNuria Juanpere
Nuria Juanpere
SMSilvia de Muga
Silvia de Muga
MLMarta Lorenzo
Marta Lorenzo
JGJoan Gil
Joan Gil
JTJosep Lloreta Trull
Josep Lloreta Trull
ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression

11 January 2013 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
SMSilvia de Muga
Silvia de Muga
SHSilvia Hernández
Silvia Hernández
MSMarta Salido
Marta Salido
MLMarta Lorenzo
Marta Lorenzo
LALaia Agell
Laia Agell
JLJosep Lloreta
Josep Lloreta
The TMPRSS2-ERG fusion has been reported in 42 to 78% of prostate tumors. More than 90% of ERG-overexpressing tumors harbor the fusion. The relationship between the TMPRSS2-ERG fusion and prognosis is controversial. Different studies have suggested a

28 June 2024 in medRxiv
Verified
Preprint
Open access
PDF file
AAAriadna Acedo-Terrades
Ariadna Acedo-Terrades
ARAlejo Rodriguez-Vida
Alejo Rodriguez-Vida
OBOscar Buisan
Oscar Buisan
MTMarta Bodalo Torruella
Marta Bodalo Torruella
MGMaria Gabarrós
Maria Gabarrós
JBJoaquim Bellmunt
Joaquim Bellmunt
Muscle-invasive bladder cancer (MIBC) is associated with poor predictability of response to cisplatin-based neoadjuvant chemotherapy (NAC). Consequently, the benefit of NAC remains unclear for many patients due to the lack of reliable biomarkers. In order to identify biomarkers and build an integrated and accurate model to predict NAC response, we conducted a comprehensive transcriptomic and genomic profiling on 100 MIBC patient tumors. Our analysis identified 602 differentially expressed genes between responders and non responders. From these, we derived the Top10up and Top10dn gene signatures. We also identified a set of genes related to keratinization (KRT), extracellular matrix (ECM) and cell cycle regulation (CELL CYCLE REG) that were strongly associated with response. Additionally, we found a Wnt-related signature (WNT) significantly associated with non response. Genomic analysis revealed that mutations in DNAH8, DNAH6 or DNAH10 (DNAHalt) and deletions in KDM6A (KDM6Adel) correlated significantly with chemotherapy resistance. Using our comprehensive molecular analysis as a backbone, we developed different machine learning (ML) models, based on the Xgboost (XGB) approach. The transcriptomics-only model (XGB-R) matched the performance of the combined model (XGB-RW; AUC=0.85). The relative ease of sample collection for transcriptomic data, along with the external validation, make it a promising candidate for clinical translation. To ensure robustness and broader applicability, external validation in larger, more diverse cohorts is necessary. To facilitate this, our most predictive ML models have been made publicly available via GitHub. Statement of significance: We present XGB-R, a robust validated machine-learning model using transcriptomic features to predict neoadjuvant chemotherapy response in muscle-invasive bladder cancer with high accuracy (AUC=0.85), being a candidate for clinical translation.